ArticleImmunologic research2025
Role of the basophil activation test in the diagnosis and management of immediate drug reaction to injectable growth hormone preparation: a case report.
Article in Immunologic research, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Hypersensitivity reactions to synthetic hormones are rare but can represent serious complications. Allergic responses to synthetic human growth hormone (rhGH) pharmaceutical preparations are uncommon. Despite their rarity, such reactions pose a significant clinical dilemma due to the associated risks and implications for ongoing treatment. Diagnosis is further complicated by the absence of standardized and commercially available in vitro tests, while in vivo testing carries the risk of systemic reactions, even at high dilutions. We report the case of a 6-year-old patient who experienced a severe reaction following rhGH administration. The diagnosis was investigated using the basophil activation test (BAT) prior to any in vivo testing. Given the potential risks of in vivo diagnostics, as previously reported in the literature, the BAT was employed to confirm the diagnosis and to identify a safe alternative rhGH formulation, which yielded negative results both in BAT and subsequent in vivo testing.
Indexed as
Identifiers
40465134What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.